XJPX
4524
Market cap57mUSD
Oct 09, Last price
2,210.00JPY
1D
-0.85%
1Q
1.84%
Jan 2017
-19.49%
Name
Morishita Jintan Co Ltd
Chart & performance
P/E
14.42
P/S
0.71
EPS
153.22
Div yield, %
2.47%
Shrs. gr., 5y
0.11%
Rev. gr., 5y
6.12%
Revenues
12.69b
-0.61%
Net income
628m
+14.81%
CFO
1.15b
+71.90%
Dividend
Mar 30, 202765 JPY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Morishita Jintan Co., Ltd. is a Japanese enterprise that manufactures and distributes a diverse array of products, encompassing pharmaceuticals, quasi-pharmaceuticals, medical devices, and food items. The company's operations are divided into two main segments: Healthcare Business and Capsule Business. The Healthcare Business division is responsible for the production and sale of its proprietary Jintan branded goods, and also provides original equipment manufacturing (OEM) services for dietary supplements, cosmetic products, and various food items. Concurrently, the Capsule Business division handles both original equipment and design manufacturing (OEM/ODM) for pharmaceutical and food sectors, in addition to innovating and developing capsules for industrial applications. Established in 1893, the company's headquarters are located in Osaka, Japan.
Key people
Hidetsugu Ishida
Managing Executive Officer, Chief Director of Research and Development · since 2025
Shinichi Takada
Managing Executive Officer, Director of Administration · since 2007
Fumitaka Takesada
Managing Executive Officer, Chief Director of Administration, Director · since 2014
Kazumi Ito
Executive Officer, Chief Director of Business Promotion, Director of Solutions Business · since 2025
Noriyuki Jinushi
Executive Officer, Manager of Business Planning · since 2022
Hiroaki Kobayashi
Executive Officer, Chief Director of Production · since 2025
Yuji Morishita
President, Chief Executive Officer, President of Subsidiary, Representative Director · since 2023
Hideaki Yoshida
Executive Officer, Chief Director of Administration, Director · since 2024
Independent Director · since 2020
Mayumi Ishihara
Independent Director · since 2018
Independent Director · since 2024
Hiroaki Ohshiro
Independent Director · since 2024
Independent Director · since 2020
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||